Synthetic Biologics Inc (SYN) Sees Large Drop in Short Interest

Synthetic Biologics Inc (NYSE:SYN) saw a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 9,312,299 shares, a drop of 7.4% from the September 15th total of 10,051,188 shares. Based on an average daily volume of 350,088 shares, the days-to-cover ratio is presently 26.6 days. Currently, 12.5% of the company’s stock are short sold.

A number of equities research analysts have recently commented on the company. BTIG Research assumed coverage on Synthetic Biologics in a research report on Thursday, August 25th. They set a “buy” rating and a $5.00 price target on the stock. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a report on Tuesday, August 9th. Griffin Securities set a $5.80 price objective on Synthetic Biologics and gave the stock a “buy” rating in a report on Wednesday, August 31st. Finally, FBR & Co reiterated a “buy” rating on shares of Synthetic Biologics in a report on Friday, August 5th.

Several large investors have recently added to or reduced their stakes in SYN. Vanguard Group Inc. raised its stake in Synthetic Biologics by 10.5% in the second quarter. Vanguard Group Inc. now owns 2,761,194 shares of the company’s stock worth $4,970,000 after buying an additional 262,551 shares during the period. BlackRock Fund Advisors raised its stake in Synthetic Biologics by 1,271.8% in the second quarter. BlackRock Fund Advisors now owns 1,967,983 shares of the company’s stock worth $3,542,000 after buying an additional 1,824,521 shares during the period. BlackRock Institutional Trust Company N.A. raised its stake in Synthetic Biologics by 53.8% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,779,542 shares of the company’s stock worth $3,203,000 after buying an additional 622,316 shares during the period. State Street Corp raised its stake in Synthetic Biologics by 1,530.4% in the second quarter. State Street Corp now owns 874,463 shares of the company’s stock worth $1,573,000 after buying an additional 820,829 shares during the period. Finally, BlackRock Investment Management LLC raised its stake in Synthetic Biologics by 2,517.2% in the second quarter. BlackRock Investment Management LLC now owns 282,158 shares of the company’s stock worth $508,000 after buying an additional 271,377 shares during the period.

Synthetic Biologics (NYSE:SYN) opened at 1.58 on Friday. The company’s 50 day moving average price is $1.69 and its 200-day moving average price is $1.92. Synthetic Biologics has a 12-month low of $0.93 and a 12-month high of $3.09. The company’s market capitalization is $144.21 million.

Synthetic Biologics (NYSE:SYN) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. Equities analysts forecast that Synthetic Biologics will post ($0.39) earnings per share for the current fiscal year.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

5 Day Chart for NYSE:SYN

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Disney to Build Larger Hong Kong Kingdom
Disney to Build Larger Hong Kong Kingdom


 
© 2006-2016 Ticker Report. Google+.